Work

Using An Economic Model To Choose Initial Appropriate Antibiotic Therapy Based On Differences In In-Vitro Susceptibility To Ceftolozane/Tazobactam And Piperacillin/Tazobactam

Year: 2015

Type: article

Source: Value in Health

DOI: 10.1016/j.jval.2015.09.1680

Authors: V Prabhu, S Sen, B Miller, A Basu, G Medic

Institutions: Merck & Co., Inc., Rahway, NJ, USA (United States), University of Washington

Language: English

Topic: Antibiotic Use and Resistance

Subfield: Applied Microbiology and Biotechnology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2157825034

FWCI: 0.301

Cites: 7

Cited by: 2

Related to: 10